W Victoria Lai1, Louisiane Lebas2, Tristan A Barnes3, Julie Milia2, Ai Ni1, Oliver Gautschi4, Solange Peters5, Roberto Ferrara6, Andrew J Plodkowski7, John Kavanagh8, Joshua K Sabari9, Stephen J Clarke10, Nick Pavlakis10, Alexander Drilon1, Charles M Rudin1, Maria E Arcila1, Natasha B Leighl11, Frances A Shepherd11, Mark G Kris1, Julien Mazières2, Bob T Li12. 1. Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Toulouse University Hospital, Toulouse, France. 3. Princess Margaret Cancer Centre, Toronto, Canada(2); Northern Beaches Cancer Service, Manly NSW Australia(3). 4. Lucerne Cantonal Hospital, Lucerne, Switzerland. 5. Lausanne University Hospital, Lausanne, Switzerland. 6. Gustave Roussy, Villejuif, France. 7. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8. Toronto General Hospital, University Health Network and University of Toronto, Toronto, Canada. 9. Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; New York University Langone Health, Laura and Isaac Perlmutter Cancer Center, New York, NY, USA(3). 10. Royal North Shore Hospital, University of Sydney, Sydney, Australia. 11. Princess Margaret Cancer Centre, Toronto, Canada(2). 12. Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: lib1@mskcc.org.
Abstract
INTRODUCTION: HER2 mutations occur in 1-3% of lung adenocarcinomas. With increasing use of next-generation sequencing at diagnosis, more patients with HER2-mutant tumours present for treatment. Few data are available to describe the clinical course and outcomes of these patients when treated with afatinib, a pan-HER inhibitor. METHODS: We identified patients with metastatic or recurrent HER2-mutant lung adenocarcinomas treated with afatinib among seven institutions across Europe, Australia, and North America between 2009 and 2017. We determined the partial response rate to afatinib, types of HER2 mutations, duration of response, time on treatment, and survival. RESULTS: We collected information on 27 patients with stage IV or recurrent HER2-mutant lung adenocarcinomas treated with afatinib. Of 23 patients evaluable for response, three partial responses were noted (13%, 95% confidence interval [CI] 4-33%). In addition, 57% of patients (13/23) had stable disease, and 30% (7/23) had progressive disease. We documented partial responses in patients with HER2 exon 20 insertions, including two with YVMA insertion and one with VAG insertion. Two patients with partial responses were previously treated with trastuzumab and pertuzumab. Median duration of response to afatinib was 6 months (range 5-10); median time on treatment was 3 months (range 1-30) and median overall survival from the date of diagnosis of metastatic or recurrent disease was 23 months (95% CI 18-53 months). CONCLUSIONS: Afatinib is modestly active in patients with HER2-mutant lung adenocarcinomas, including responses after progression on prior HER2-targeted therapies. However, investigations into the biology of HER2-mutant lung adenocarcinomas and development of better HER2-directed therapies are warranted.
INTRODUCTION:HER2 mutations occur in 1-3% of lung adenocarcinomas. With increasing use of next-generation sequencing at diagnosis, more patients with HER2-mutant tumours present for treatment. Few data are available to describe the clinical course and outcomes of these patients when treated with afatinib, a pan-HER inhibitor. METHODS: We identified patients with metastatic or recurrent HER2-mutant lung adenocarcinomas treated with afatinib among seven institutions across Europe, Australia, and North America between 2009 and 2017. We determined the partial response rate to afatinib, types of HER2 mutations, duration of response, time on treatment, and survival. RESULTS: We collected information on 27 patients with stage IV or recurrent HER2-mutant lung adenocarcinomas treated with afatinib. Of 23 patients evaluable for response, three partial responses were noted (13%, 95% confidence interval [CI] 4-33%). In addition, 57% of patients (13/23) had stable disease, and 30% (7/23) had progressive disease. We documented partial responses in patients with HER2 exon 20 insertions, including two with YVMA insertion and one with VAG insertion. Two patients with partial responses were previously treated with trastuzumab and pertuzumab. Median duration of response to afatinib was 6 months (range 5-10); median time on treatment was 3 months (range 1-30) and median overall survival from the date of diagnosis of metastatic or recurrent disease was 23 months (95% CI 18-53 months). CONCLUSIONS:Afatinib is modestly active in patients with HER2-mutant lung adenocarcinomas, including responses after progression on prior HER2-targeted therapies. However, investigations into the biology of HER2-mutant lung adenocarcinomas and development of better HER2-directed therapies are warranted.
Authors: Maria E Arcila; Jamie E Chaft; Khedoudja Nafa; Sinchita Roy-Chowdhuri; Christopher Lau; Michael Zaidinski; Paul K Paik; Maureen F Zakowski; Mark G Kris; Marc Ladanyi Journal: Clin Cancer Res Date: 2012-07-03 Impact factor: 12.531
Authors: J De Grève; E Teugels; C Geers; L Decoster; D Galdermans; J De Mey; H Everaert; I Umelo; P In't Veld; D Schallier Journal: Lung Cancer Date: 2012-02-10 Impact factor: 5.705
Authors: Hisayuki Shigematsu; Takao Takahashi; Masaharu Nomura; Kuntal Majmudar; Makoto Suzuki; Huei Lee; Ignacio I Wistuba; Kwun M Fong; Shinichi Toyooka; Nobuyoshi Shimizu; Takehiko Fujisawa; John D Minna; Adi F Gazdar Journal: Cancer Res Date: 2005-03-01 Impact factor: 12.701
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: D Li; L Ambrogio; T Shimamura; S Kubo; M Takahashi; L R Chirieac; R F Padera; G I Shapiro; A Baum; F Himmelsbach; W J Rettig; M Meyerson; F Solca; H Greulich; K-K Wong Journal: Oncogene Date: 2008-04-14 Impact factor: 9.867
Authors: Samanthi A Perera; Danan Li; Takeshi Shimamura; Maria G Raso; Hongbin Ji; Liang Chen; Christa L Borgman; Sara Zaghlul; Kathleyn A Brandstetter; Shigeto Kubo; Masaya Takahashi; Lucian R Chirieac; Robert F Padera; Roderick T Bronson; Geoffrey I Shapiro; Heidi Greulich; Matthew Meyerson; Ulrich Guertler; Pilar Garin Chesa; Flavio Solca; Ignacio I Wistuba; Kwok-Kin Wong Journal: Proc Natl Acad Sci U S A Date: 2009-01-02 Impact factor: 11.205
Authors: Michael Offin; Daniel Feldman; Ai Ni; Mackenzie L Myers; W Victoria Lai; Elena Pentsova; Adrienne Boire; Mariza Daras; Emmet J Jordan; David B Solit; Maria E Arcila; David R Jones; James M Isbell; Kathryn Beal; Robert J Young; Charles M Rudin; Gregory J Riely; Alexander Drilon; Viviane Tabar; Lisa M DeAngelis; Helena A Yu; Mark G Kris; Bob T Li Journal: Cancer Date: 2019-08-30 Impact factor: 6.860
Authors: Tejas Patil; Rao Mushtaq; Sydney Marsh; Christine Azelby; Miheer Pujara; Kurtis D Davies; Dara L Aisner; William T Purcell; Erin L Schenk; Jose M Pacheco; Paul A Bunn; D Ross Camidge; Robert C Doebele Journal: Clin Lung Cancer Date: 2019-11-21 Impact factor: 4.785
Authors: Harvey W Smith; Lei Yang; Chen Ling; Arlan Walsh; Victor D Martinez; Jonathan Boucher; Dongmei Zuo; Ethan S Sokol; Dean C Pavlick; Garrett M Frampton; Juliann Chmielecki; Laura M Jones; Philippe P Roux; William W Lockwood; William J Muller Journal: Proc Natl Acad Sci U S A Date: 2020-07-29 Impact factor: 11.205
Authors: Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo Journal: Curr Oncol Rep Date: 2020-04-16 Impact factor: 5.075
Authors: Dhivya R Sudhan; Angel Guerrero-Zotano; Helen Won; Paula González Ericsson; Alberto Servetto; Mariela Huerta-Rosario; Dan Ye; Kyung-Min Lee; Luigi Formisano; Yan Guo; Qi Liu; Lisa N Kinch; Monica Red Brewer; Teresa Dugger; James Koch; Michael J Wick; Richard E Cutler; Alshad S Lalani; Richard Bryce; Alan Auerbach; Ariella B Hanker; Carlos L Arteaga Journal: Cancer Cell Date: 2020-01-23 Impact factor: 31.743